Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

Prescribed List as of 1 May 2022

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made on 21 March 2022

Decision Reference:  MD-SOSEC-2022-194

Public

Subject: DS Prescribed list as of 1 May 2022

 

Report Title: DS Prescribed list as of 1 May 2022

Exempt (Article 33(b))

Decision(s):

Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 May 2022.

Reason for Decision(s):

The Pharmaceutical Benefit Advisory Committee met to consider applications for changes to the Prescribed List and made the following recommendations:  1. Items to be added to the Prescribed List from 1 May 2022  1.1 Cavilon Durable Barrier Cream for the prevention of incontinence associated skin damage 1.2 Edoxaban 15mg, 30mg, 60mg tablets for the treatment and prevention of thromboembolism, including use in patients with atrial fibrillation to prevent stroke 1.3 Fluorouracil 0.5% combined with 10% salicylic acid (Actikerall) cutaneous solution for the treatment of actinic keratosis 1.4 Liothyronine 5mcg tablets, 10mcg tablets for the treatment of hypothyroidism 1.5 Ivermectin cream (Soolantra) 10mg/g for the treatment of rosacea  2. Items to be removed from the Prescribed List from 1 August 2022  The following products are either not suitable for prescribing in primary care (item 2.1 Zuclopenthixol) or have been discontinued (all other products) and so are recommended for removal from the Prescribed List. There are alternative products available on the List.   2.1 Zuclopenthixol Acetate 50mg/1mL solution for injection ampoules 2.2 Codeine 60mg/1mL solution for injection ampoules 2.3 Cyclo-Progynova 1mg and 2mg tablets 2.4 Diprobase cream/ointment 2.5 Haloperidol 500microgram capsules 2.6 Theophylline 60/125/250mg modified release capsules 2.7 Theophylline 175mg modified release tablets 2.8 Tinidazole 500mg tablets 2.9 Aveeno Bath Oil 2.10 Sodium cromoglicate 5mg/dose inhaler CFC free (Intal®)  3. Other recommendations  3.1 Dorzolamide/timolol unit dose eye drops – proposal to retain this presentation following recommendation on 15th July 2021 to remove in favour of Eylamdo and Eydelto multi-dose preparations

Resource Implications: The overall financial impact is expected to be an increase in net annual expenditure of up to £50,000.

 

Action Required: Health Zone Manager at Customer and Local Services to issue a public notice listing amendments and notify all approved medical practitioners and approved contractors.

Signature:

 

 

Signed By: Minister for Social Security

Date Signed:

 

 

Date of Decision (If different from Date Signed):

 

 

Back to top
rating button